KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia

Leukemia. 2020 Oct;34(10):2780-2784. doi: 10.1038/s41375-020-0978-7. Epub 2020 Jul 17.

Disha Malani¹, Bhagwan Yadav², Ashwini Kumar², Swapnil Potdar², Mika Kontro^{2

3

4}, Matti Kankainen³, Komal K Javarappa², Kimmo Porkka^{3

4}, Maija Wolf², Tero Aittokallio^{2

5}, Krister Wennerberg^{2

6}, Caroline A Heckman², Astrid Murumägi², Olli Kallioniemi^{2

7}

¹ Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland. disha.malani@helsinki.fi.
² Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
³ Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
⁴ Department of Hematology, University Hospital Comprehensive Cancer Center, Helsinki, Finland.
⁵ Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, and Oslo Centre for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway.
⁶ Biotech Research & Innovation Centre, BRIC and Novo Nordisk Foundation Center for Stem Cell Biology, DanStem, University of Copenhagen, Copenhagen, Denmark.
⁷ Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet, Solna, Sweden.

No abstract available

Publication types